Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Government has committed to providing up to $2.1bn to Sanofi and GlaxoSmithKline (GSK) for development, manufacturing, scale-up and delivery of an initial 100 million doses of the companies’ Covid-19 vaccine candidate.
Based on Sanofi’s recombinant protein technology, the vaccine candidate utilises GSK’s pandemic adjuvant technology. A Phase I/II clinical trial of the product is expected to begin in September, with a Phase III study being planned for the end of the year.
This partnership with the US Department of Health and Human Services (HHS) and the Department of Defense is expected to fund the development and.